SkyOak Wealth LLC Has $14.90 Million Stock Holdings in Eli Lilly and Company $LLY

SkyOak Wealth LLC lessened its stake in shares of Eli Lilly and Company (NYSE:LLY) by 3.0% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 16,205 shares of the company’s stock after selling 509 shares during the period. Eli Lilly and Company accounts for about 2.7% of SkyOak Wealth LLC’s portfolio, making the stock its 8th biggest position. SkyOak Wealth LLC’s holdings in Eli Lilly and Company were worth $14,905,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently bought and sold shares of the company. Norges Bank bought a new position in shares of Eli Lilly and Company in the 4th quarter valued at $12,976,634,000. J. Stern & Co. LLP grew its holdings in shares of Eli Lilly and Company by 46,191.3% during the 4th quarter. J. Stern & Co. LLP now owns 4,047,245 shares of the company’s stock valued at $4,047,245,000 after purchasing an additional 4,038,502 shares during the last quarter. Cardano Risk Management B.V. lifted its stake in Eli Lilly and Company by 876.1% in the 4th quarter. Cardano Risk Management B.V. now owns 2,375,050 shares of the company’s stock valued at $2,552,419,000 after purchasing an additional 2,131,734 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its position in Eli Lilly and Company by 10.6% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 14,910,505 shares of the company’s stock valued at $16,024,022,000 after buying an additional 1,432,069 shares in the last quarter. Finally, Assenagon Asset Management S.A. lifted its stake in shares of Eli Lilly and Company by 353.7% in the 1st quarter. Assenagon Asset Management S.A. now owns 1,550,234 shares of the company’s stock valued at $1,425,859,000 after acquiring an additional 1,208,510 shares during the last quarter. 82.53% of the stock is owned by institutional investors.

Eli Lilly and Company Stock Down 0.0%

Shares of Eli Lilly and Company stock opened at $1,215.41 on Friday. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $1,249.45. The company has a quick ratio of 1.10, a current ratio of 1.50 and a debt-to-equity ratio of 1.26. The company’s 50 day moving average is $1,091.91 and its 200 day moving average is $1,032.43. The company has a market cap of $1.14 trillion, a price-to-earnings ratio of 43.18, a price-to-earnings-growth ratio of 1.51 and a beta of 0.51.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Thursday, April 30th. The company reported $8.55 EPS for the quarter, topping the consensus estimate of $6.97 by $1.58. The company had revenue of $19.80 billion during the quarter, compared to analyst estimates of $17.82 billion. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.Eli Lilly and Company’s revenue was up 55.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $3.34 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Research analysts anticipate that Eli Lilly and Company will post 35.81 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 10th. Investors of record on Friday, August 14th will be given a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a yield of 0.6%. The ex-dividend date is Friday, August 14th. Eli Lilly and Company’s payout ratio is 24.58%.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on LLY shares. Leerink Partners boosted their price target on Eli Lilly and Company from $1,119.00 to $1,232.00 and gave the stock an “outperform” rating in a report on Thursday, June 25th. Guggenheim reaffirmed a “buy” rating and set a $1,183.00 price target on shares of Eli Lilly and Company in a research note on Tuesday, May 5th. Wolfe Research restated an “outperform” rating and issued a $1,350.00 price objective on shares of Eli Lilly and Company in a report on Thursday, May 21st. BMO Capital Markets reissued an “outperform” rating on shares of Eli Lilly and Company in a research note on Monday, June 15th. Finally, Rothschild & Co Redburn lifted their price objective on Eli Lilly and Company from $880.00 to $900.00 in a research note on Thursday, May 7th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $1,260.33.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Record use of GLP-1 drugs in the U.S. is supporting Eli Lilly’s best-selling obesity treatment business, with sales momentum accelerating for the company’s leading drug franchise. Record Numbers of Americans Are on GLP-1 Drugs. That’s Great News for This Stock.
• Positive Sentiment: Royal Bank of Canada raised its price target on LLY to $1,500 and kept an outperform rating, reinforcing Wall Street’s bullish view on Lilly’s growth outlook and drug demand. Eli Lilly and Company (NYSE:LLY) Given New $1,500.00 Price Target at Royal Bank Of Canada
• Positive Sentiment: Lilly announced new Alzheimer’s disease research presentations for AAIC 2026, including data on Kisunla and P-tau217 blood tests, highlighting a broader pipeline beyond weight-loss drugs. Lilly to present Alzheimer’s disease diagnostic and therapeutic research at AAIC 2026, including new data on P-tau217 blood tests and amyloid-targeting treatment
• Positive Sentiment: Canadian regulators gave a positive recommendation for Lilly’s eczema treatment, adding another potential growth driver outside obesity and diabetes. Eli Lilly Stock (LLY) Gets a Boost as Eczema Treatment Receives a Positive Recommendation in Canada
• Neutral Sentiment: Tampa General Hospital sued Eli Lilly over alleged removal of 340B discounts, creating a legal and pricing overhang, though the financial impact is still uncertain. Tampa General sues Eli Lilly for allegedly pulling 340B discounts

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.